$0.32
0.37% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Marinus Pharmaceuticals Inc Stock price

$0.32
-0.08 20.07% 1M
-1.06 76.54% 6M
-10.55 97.02% YTD
-5.98 94.86% 1Y
-11.51 97.26% 3Y
-3.92 92.36% 5Y
-26.72 98.80% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.37%
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Key metrics

Market capitalization $17.87m
Enterprise Value $70.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.25
P/S ratio (TTM) P/S ratio 0.57
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1.63%
Revenue (TTM) Revenue $31.47m
EBIT (operating result TTM) EBIT $-122.62m
Free Cash Flow (TTM) Free Cash Flow $-115.93m
Cash position $42.18m
EPS (TTM) EPS $-2.47
P/E forward negative
P/S forward 0.50
EV/Sales forward 1.98
Short interest 10.32%
Show more

Is Marinus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Marinus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

3x Buy
30%
7x Hold
70%

Analyst Opinions

10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

Buy
30%
Hold
70%

Financial data from Marinus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
31 31
2% 2%
100%
- Direct Costs 3.62 3.62
77% 77%
12%
28 28
4% 4%
88%
- Selling and Administrative Expenses 63 63
5% 5%
199%
- Research and Development Expense 87 87
7% 7%
277%
-122 -122
2% 2%
-388%
- Depreciation and Amortization 0.53 0.53
25% 25%
2%
EBIT (Operating Income) EBIT -123 -123
2% 2%
-390%
Net Profit -140 -140
5% 5%
-446%

In millions USD.

Don't miss a Thing! We will send you all news about Marinus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marinus Pharmaceuticals Inc Stock News

Neutral
Business Wire
14 days ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy ...
Neutral
Business Wire
about one month ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint o...
Neutral
Business Wire
about one month ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting...
More Marinus Pharmaceuticals Inc News

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Head office United States
CEO Scott Braunstein
Employees 165
Founded 2003
Website www.marinuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today